Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective hoisted by Stifel Nicolaus from $180.00 to $205.00 in a research report report published on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Zacks Investment Research raised Jazz Pharmaceuticals from a hold rating to a buy rating and set a $189.00 target price on the stock in a report on Thursday, May 31st. Royal Bank of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the company a buy rating in a report on Friday, June 1st. Wells Fargo & Co reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Sunday, July 8th. Morgan Stanley lowered Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 target price on the stock. in a report on Wednesday, July 11th. Finally, BMO Capital Markets boosted their target price on Jazz Pharmaceuticals from $199.00 to $201.00 and gave the company an outperform rating in a report on Wednesday, May 9th. One analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $188.67.

Shares of Jazz Pharmaceuticals traded down $1.62, reaching $176.11, during trading on Wednesday, Marketbeat.com reports. The company had a trading volume of 419,330 shares, compared to its average volume of 423,344. The firm has a market cap of $10.61 billion, a P/E ratio of 18.42, a PEG ratio of 0.96 and a beta of 0.90. The company has a current ratio of 3.76, a quick ratio of 2.88 and a debt-to-equity ratio of 0.54. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.23 by $0.26. The business had revenue of $500.48 million for the quarter, compared to analyst estimates of $469.85 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. research analysts forecast that Jazz Pharmaceuticals will post 11.64 EPS for the current fiscal year.

In related news, CEO Bruce C. Cozadd sold 7,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $168.86, for a total value of $1,182,020.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $164.68, for a total value of $32,936.00. Following the completion of the sale, the executive vice president now owns 26,122 shares in the company, valued at $4,301,770.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,620 shares of company stock worth $3,168,752. Company insiders own 3.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of JAZZ. Envestnet Asset Management Inc. boosted its position in Jazz Pharmaceuticals by 591.3% during the second quarter. Envestnet Asset Management Inc. now owns 5,171 shares of the specialty pharmaceutical company’s stock worth $891,000 after purchasing an additional 4,423 shares in the last quarter. AGF Investments Inc. purchased a new stake in Jazz Pharmaceuticals during the second quarter worth $78,345,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Jazz Pharmaceuticals during the second quarter worth $277,000. FMR LLC boosted its position in Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after purchasing an additional 715,595 shares in the last quarter. Finally, Tiverton Asset Management LLC purchased a new stake in Jazz Pharmaceuticals during the second quarter worth $198,000. Hedge funds and other institutional investors own 90.00% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Leveraged Buyout (LBO)

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.